Idiopathic Pulmonary Fibrosis Treatment Market Size, Share, Trends, Analysis and Forecast 2021-2026
According to the latest report by IMARC Group, titled “Idiopathic Pulmonary Fibrosis Treatment Market Size: Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026,” the global idiopathic pulmonary fibrosis treatment market size to reach a value of US$ 4.91 Billion by 2026.
Idiopathic pulmonary fibrosis (IPF) refers to a chronic lung disease that causes the buildup of scar tissues in the lungs. This condition hinders the oxygen-carrying functionality of the lungs, thus resulting in breathing difficulties. IPF is diagnosed through various chest imaging evaluations, including lung biopsies, antibody tests, and pulmonary function tests. It can be treated through anti-fibrotic drugs and supportive treatment options, such as oxygen therapy and palliative care.
Idiopathic Pulmonary Fibrosis Treatment Market Trends:
The increasing prevalence of fibrotic diseases, especially in the geriatric population, and a rise in the cigarette smoking population are majorly fueling the global IPF treatment market growth. Additionally, increasing health consciousness amongst consumers and the rising awareness regarding the effective prevention and management strategies of IPF are further supporting the market growth. Moreover, rising investments in improving the healthcare infrastructure and extensive research and development (R&D) activities for introducing novel medicines for IPF are creating a positive outlook for the market.
Request Free Sample Report:
Idiopathic Pulmonary Fibrosis Treatment Market 2021-2026 Analysis and Segmentation:
The competitive landscape of the market has been studied in the report with the detailed profiles of the key players operating in the market.
AdAlta Pty Ltd., Angion Biomedica Corp., Boehringer Ingelheim International GmbH (C. H. Boehringer Sohn AG & Co. KG), Bristol-Myers Squibb Company, Cipla Inc., F. Hoffmann-La Roche AG (Roche Holding AG), Fibrogen Inc., Galapagos NV, Liminal BioSciences Inc., Medicinova Inc., Merck & Co. Inc., Novartis AG and Vectura Group Plc.
The report has segmented the market on the basis on region, drug class and end user.
Breakup by Drug Class:
- MAPK Inhibitors
- Tyrosine Inhibitors
- Autotaxin Inhibitors
Breakup by End User:
- Long-term Care Facilities
Breakup by Region:
- North America: United States, Canada
- Asia Pacific: China, Japan, India, South Korea, Australia, Indonesia, Others
- Europe: Germany, France, United Kingdom, Italy, Spain, Russia, Others
- Latin America: Brazil, Mexico, Other
- Middle East and Africa
Ask Analyst for Customization and Explore Full Report with TOC & List of Figure: https://www.imarcgroup.com/idiopathic-pulmonary-fibrosis-treatment-market
If you want latest primary and secondary data (2021-2026) with Cost Module, Business Strategy, Distribution Channel, etc. Click request free sample report, published report will be delivered to you in PDF format via email within 24 to 48 hours of receiving full payment.
Key highlights of the report:
- Market Performance (2015-2020)
- Market Outlook (2021- 2026)
- Porter’s Five Forces Analysis
- Market Drivers and Success Factors
- SWOT Analysis
- Value Chain
- Comprehensive Mapping of the Competitive Landscape
If you need specific information that is not currently within the scope of the report, we can provide it to you as a part of the customization.
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.
30 N Gould St Ste R
Sheridan, WY 82801 USA – Wyoming
Tel No:(D) +91 120 433 0800
Americas:- +1 631 791 1145 | Africa and Europe :- +44-702-409-7331 | Asia: +91-120-433-0800, +91-120-433-0800